- Trials with a EudraCT protocol (334)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
334 result(s) found for: HCC.
Displaying page 1 of 17.
EudraCT Number: 2004-002834-20 | Sponsor Protocol Number: HCC-Rap-001 | Start Date*: 2008-01-23 |
Sponsor Name:Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie | ||
Full Title: Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001) Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Ra... | ||
Medical condition: Advanced hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004505-34 | Sponsor Protocol Number: 201800881 | Start Date*: 2021-02-17 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with advanced untreatable hepatocellular carcinoma | ||
Medical condition: The anti-tumoral effect of cannabis oil will be investigated in patients with untreatable HCC | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005386-67 | Sponsor Protocol Number: 20140318 | Start Date*: 2017-03-27 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b an... | ||||||||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005362-36 | Sponsor Protocol Number: SiLVER 05 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:Regensburg University Hospital | |||||||||||||
Full Title: A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Prophylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) BE (Completed) NO (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000566-23 | Sponsor Protocol Number: GK-001-01 | Start Date*: 2008-08-25 | |||||||||||
Sponsor Name:GeneCare Research Institute Co., Ltd. | |||||||||||||
Full Title: A randomized phase 2 double-blind, placebo-controlled study of GK-001 in hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment Estudio aleatorizado de ... | |||||||||||||
Medical condition: hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment carcinoma hepatocelular (CHC) en pacientes con hepatitis C crónica tras tratamiento curativo para... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002843-92 | Sponsor Protocol Number: BA2011/03/04 | Start Date*: 2013-05-27 |
Sponsor Name:Onxeo | ||
Full Title: Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to ... | ||
Medical condition: Advanced Hepatocellular Carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) ES (Completed) HU (Completed) AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003741-42 | Sponsor Protocol Number: 31031981 | Start Date*: 2014-05-06 |
Sponsor Name:Medizinische Universität Innsbruck, Abteilung für Nuklearmedizin | ||
Full Title: PROSPECTIVE STUDY OF [68GA]NODAGA-RGD-PET FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND THE ASSESSMENT OF TREATMENT RESPONSE | ||
Medical condition: This trial investigates a new tracer substance for PET scan of hepatocellular carcinoma in patients with liver disease. The condition investigated is a hepatocellular carcinoma in patients with liv... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003553-42 | Sponsor Protocol Number: AIO-HEP-0217 | Start Date*: 2018-05-03 | ||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||||||||||||
Full Title: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) | ||||||||||||||||||||||||||||
Medical condition: intermediate stage hepatocellular carcinoma (HCC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002930-62 | Sponsor Protocol Number: GDX-44-008 | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:GUERBET | |||||||||||||
Full Title: Proof of Concept study concerning efficacy of P03277 MR Imaging in HCC diagnosis Phase IIa Clinical Study | |||||||||||||
Medical condition: liver nodules of less or equal to 3 cm suspected for HCC in subjects with chronic liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008652-16 | Sponsor Protocol Number: BR1-129 | Start Date*: 2009-10-01 | |||||||||||
Sponsor Name:BRACCO IMAGING | |||||||||||||
Full Title: QUANTITATIVE EVALUATION OF SONOVUE ENHANCED ULTRASONOGRAPHY FOR EARLY IDENTIFICATION OF SUBJECTS WITH HEPATOCELLULAR CARCINOMA REFRACTORY TO SORAFENIB THERAPY : A PHASE II EXPLORATIVE, INTRA-PATIEN... | |||||||||||||
Medical condition: HCC epatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000963-41 | Sponsor Protocol Number: 104-06-301 | Start Date*: 2008-12-03 | |||||||||||
Sponsor Name:CELSION CORPORATION | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (R... | |||||||||||||
Medical condition: patients with Non-Resectable Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000234-42 | Sponsor Protocol Number: FAB0001 | Start Date*: 2022-05-27 | |||||||||||
Sponsor Name:Medical University of Vienna, Div. of Gastroenterology & Hepatology | |||||||||||||
Full Title: Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC Trial | |||||||||||||
Medical condition: Hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000730-40 | Sponsor Protocol Number: SOCRATES | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Heinrich-Heine-Universität Düsseldorf | |||||||||||||
Full Title: Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC) | |||||||||||||
Medical condition: histologically proven advanced hepatocellular carcinoma (HCC) not suitable for resection or liver transplantation but without extrahepatic manifestations and without previous treatment for HCC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003925-17 | Sponsor Protocol Number: HCC-PBMC-GM-CSF | Start Date*: 2008-10-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation | |||||||||||||
Medical condition: patients with hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004004-60 | Sponsor Protocol Number: Rad-HCC | Start Date*: 2017-03-02 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient. | |||||||||||||
Medical condition: patients with HCC in the setting of cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002609-31 | Sponsor Protocol Number: ISO-44-013 | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:Guerbet | |||||||||||||
Full Title: Diagnostic contribution of XENETIX® CT PERFUSION in pre-therapeutical assessment of hepatocellular carcinoma. | |||||||||||||
Medical condition: Subjects diagnosed for HCC and planned for surgery (tumorectomy, sectionectomy, segmentectomy, lobectomy or transplantation). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002893-23 | Sponsor Protocol Number: H8Z-MC-JACS | Start Date*: 2009-09-03 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma | ||
Medical condition: Hepatocellular Carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004437-20 | Sponsor Protocol Number: JS001-027-III-HCC | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Shanghai Junshi Biosciences Co., Ltd | ||||||||||||||||||||||||||||
Full Title: A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with l... | ||||||||||||||||||||||||||||
Medical condition: advanced hepatocellular carcinoma (HCC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002828-85 | Sponsor Protocol Number: RG_15-114 | Start Date*: 2017-04-28 | |||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||
Full Title: Paediatric Hepatic International Tumour Trial | |||||||||||||||||||||||
Medical condition: Hepatoblastoma and Hepatocellular Carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) SE (Completed) FI (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004679-29 | Sponsor Protocol Number: P171001J | Start Date*: 2018-06-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial | |||||||||||||
Medical condition: Nivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
